Indeed, in vitro and in vivo pharmacological manipulations aimed at boosting cGMP levels, such as NO mimetic drugs [37,38], sGC stimulators [38], and PDE inhibitors [39,40], resulted in the rescue of Aβ/tau-induced synaptic and cognitive deficits. Here, SGCB is linked to Cognitive impairment.